US2015011581A1PendingUtilityA1
Treatment of progressive neurodegenerative disease with ibudilast
Est. expiryJul 11, 2027(~1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/16A61P 25/28A61P 25/14A61P 25/00A61P 21/00A61K 9/0019A61K 9/0053A61K 45/06A61K 9/0014A61K 31/437A61K 9/06
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a patient diagnosed with amyotrophic lateral sclerosis (ALS) comprising administering to a patient in need thereof a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least six months.
3 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least one year.
4 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least two years.
5 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily.
6 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally.
7 . The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in an amount of 30 mg to 240 mg daily.Join the waitlist — get patent alerts
Track US2015011581A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.